A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have obesity or overweight
If overweight, must also have one of the following: High blood pressure, high cholesterol, obstructive sleep apnea or heart disease
Have at least 1 self-report of an unsuccessful at dietary effort to lose weight
Participants Must Not:
Have Type 1 diabetes, Type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening
Have family (first-degree relative) or personal history of MTC or MEN2 syndrome
Have had a history of chronic or acute pancreatitis
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo